Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02268552
Other study ID # CLMI070X2201
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date April 2, 2015
Est. completion date December 29, 2022

Study information

Verified date April 2023
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open-label, multi-part, first-in-human study of oral branaplam in infants with Type 1 spinal muscular atrophy. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy after 13 weeks; and to estimate the Maximum Tolerated Dose (MTD) of orally administered branaplam; and to identify the dose that is safe for long term use as well as that can provide durable efficacy optimal dosing regimen in patients with Type 1 SMA.


Description:

This is an open-label, multi-part, first-in-human, proof of concept study in infants with Type 1 spinal muscular atrophy who have exactly 2 copies of SMN2, to evaluate safety, tolerability, PK, PD and efficacy of oral branaplam after 13 weeks treatment. Parts 1 and 2 are intended to be non-confirmatory. In Part 1 of the study, patients will be dosed once weekly with branaplam. The branaplam dose will be escalated in subsequent cohorts until MTD is determined or when sufficient PK results confirm that the MTD cannot be reached due to a potential pharmacokinetic plateau at higher doses. A decision to dose escalate the next cohort will be made after safety data have been collected for 14 days following the first dose (14-day DLT window). PK will be used to confirm that there is no accumulation of the compound. Part 2 of the study will enroll new patients into one of up to 3 dose cohorts with once weekly dosing for 52 weeks. The branaplam dose will be escalated in subsequent cohorts after 6 patients have been enrolled and at least 3 patients from the previous cohort will have completed 13 weeks of treatment. After 52 weeks, patients may continue treatment if Novartis, the investigator and the independent DMC agree that this is in the best interest of the patient. In all cases continuation of the treatment will be done at a dose selected as optimum, considering existing safety as well as efficacy data


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 29, 2022
Est. primary completion date December 29, 2022
Accepts healthy volunteers No
Gender All
Age group 28 Days to 182 Days
Eligibility Inclusion Criteria: Common for both Parts 1 and 2: - Type 1 SMA, diagnosed clinically, with symptom onset <6 months of age and genetic confirmation of mutations in both alleles of the SMN1 gene, and with SMN2 copy number of 2. - Best supportive care in place and stable for at least 14 days before screening. - Must be able to demonstrate antigravity strength in both biceps. At birth gestational age >32 weeks and body weight at birth >2 kg. - Must live within 2 hours drive of study center. Clearance should be obtained from the site investigator and sponsor if the patient resides more than 2 hours ground travel from the study center Specific for Part 1 - Age at screening between 1 and 7 months - Must have or agree to have placement of feeding tube for enteral access via nasogastric (NG), nasojejunal (NJ), percutaneous gastrostomy (PEG), or percutaneous jejunostomy (PEJ) tube for administration of branaplam (for patients in whom branaplam cannot be administered orally ; NG tube may be removed between doses). Specific for Part 2 - Age at screening between 30 and 180 days of age - Must have or agree to have placement of feeding tube for enteral access via nasogastric (NG), nasojejunal (NJ), percutaneous gastrostomy (PEG), or percutaneous jejunostomy (PEJ) tube for administration of branaplam (for the first administration only and for patients in whom branaplam cannot be administered orally; NG tube may be removed between doses). - Minimum CHOP INTEND score of 15 at baseline - Must be able to feed orally for all nutritional needs and be greater than the 2nd percentile for weight on the standard growth curves for the country of origin Exclusion Criteria: Common for both Parts 1 and 2: - Neurologic, or neuromuscular conditions other than SMA. - Anemia, leukopenia, neutropenia or thrombocytopenia - Hepatic dysfunction - Age adjusted renal dysfunction - Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period. - Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period. - Excluding SMA, any medically unstable condition including cardiomyopathy, hepatic dysfunction, kidney disorder, endocrine disorder, GI disorders, prematurity of <32 weeks gestation, metabolic disorders, severe respiratory compromise and significant brain abnormalities or injuries including hypoxic-ischemic encephalopathy. - Current diagnosis of cardiac and/or vascular abnormalities or ECG abnormalities - Acute or ongoing medical condition that, according to the Site Investigator and discussed with sponsor, would interfere with the conduct and assessments of the study. Examples are medical disability other than SMA that would interfere with the assessment of safety or would compromise the ability of the subject to undergo study procedures including be assessed by CHOP INTEND motor scale, changes in hematologic parameters or gastrointestinal dysfunction that would compromise the ability of adequate assessment of safety Specific for Part 1 - Use of other investigational drugs within 14 days. - Intractable seizure disorder (other than inactive febrile seizures). - Persistent (in the opinion of the Investigator) hypoxemia (O2 saturation awake <92% or O2 saturation asleep <91%, without ventilation support) or requiring oral suctioning >2 per day, or presence of a tracheostomy. Specific for Part 2 - Use of nusinersen or gene transfer at any time or other investigational drugs within 14 days. - Intractable epilepsy - Persistent (in the opinion of the Investigator) hypoxemia (O2 saturation awake <92% or O2 saturation asleep <91%, without ventilation support), or presence of a tracheostomy.

Study Design


Intervention

Drug:
branaplam


Locations

Country Name City State
Belgium Novartis Investigative Site Gent
Belgium Novartis Investigative Site Leuven
Bulgaria Novartis Investigative Site Sofia
Denmark Novartis Investigative Site Copenhagen
Germany Novartis Investigative Site Essen
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Roma RM
Poland Novartis Investigative Site Warsaw
Poland Novartis Investigative Site Wroclaw
Russian Federation Novartis Investigative Site Ekaterinburg
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Volgograd

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

Belgium,  Bulgaria,  Denmark,  Germany,  Italy,  Poland,  Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with adverse events (AEs), serious adverse events (SAEs) Participants are monitored for safety throughout the study 13 weeks
Primary Number of participants with adverse events (AEs), serious adverse events (SAEs) Participants are monitored for safety throughout the study 52 weeks
Secondary Change from baseline in length To evaluate the effect of branaplam on length in cm Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study.
Secondary Change from baseline in pulse oximetry To evaluate the effect of branaplam on respiratory function by measurement of Pulse oximetry in percentage (%) of oxygen saturation Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study.
Secondary Change from baseline in Hammersmith Infant Neurology Examination (HINE) section 2 To evaluate the effect of branaplam on infant motor development using HINE section 2 Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study.
Secondary Pharmacokinetic: AUC To evaluate branaplam pharmacokinetics in plasma after single and repeated doses of branaplam by determination of AUC. Parts 1 and 2: Day 1 (Pre-dose + 1, 2, 4, 8 & 24 hours post-dose), Days 2, 3, 5, 8, 29. Part 1: Day 43. Part 2: Day 57, 57, 92 (Pre-dose + 4 & 24 hours post-dose), 94, 99, 274 (Pre-dose + 4 & 24 hours post-dose), 276, 281
Secondary In addition to the above for Part 2 - Change from baseline in feeding status To evaluate the efficacy of branaplam on preservation of oral feeding Baseline, Day 15, Day 36, Day 57, Day 88 + End of Study
Secondary In addition to the above for Part 2 - Changes in Ulnar Nerve Compound Motor Action Potential (CMAP) from baseline To evaluate the efficacy of branaplam on Ulnar and Peroneal Nerve Compound Motor Action Potentials (CMAPs) in terms of % increase from baseline Baseline, Day 88 + End of Study
Secondary In addition to the above for Part 2 - Changes from baseline on the ability to site without support To evaluate the efficacy of branaplam on the ability to sit without support 52 weeks
Secondary Change from baseline in weight To evaluate the effect of branaplam on weight in kilograms Screening, Day 1, Day 8 to Day 85. Extended treatment periods: every 4 weeks and at the End of Study
Secondary Change from baseline in head circumference To evaluate the effect of branaplam on head circumference in cm Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study.
Secondary Change from baseline in chest circumference To evaluate the effect of branaplam on chest circumference Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study.
Secondary Change from baseline in Children's Hospital of Philadelphia Infant Neuromuscular Disorders (CHOP INTEND) To evaluate the effect of branaplam on infant motor development using CHOP INTEND Part 1: Baseline, Day 36, Day 85, and every 6 to 7 weeks in the extended treatment periods, and at the End of Study. Part 2: Baseline, Day 36, Day 85, Day 127, Day 176, Day 218, Day 267, Day 309, Day 358 and End of Study
Secondary Change from baseline in respiratory rate To evaluate the effect of branaplam on respiratory function by measurement of the respiratory rate Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study.
Secondary Change from baseline in chest circumference during quiet breathing To evaluate the effect of branaplam on respiratory function by measurement of the chest circumference in cm during expiration and during inspiration Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study.
Secondary Change from baseline in paradoxical breathing To evaluate the effect of branaplam on respiratory function by evaluation of the presence of absence of paradoxical breathing Part 1 Screening, Days 1, 8 to 85. Extended treatment periods: every 4 weeks and at the end of study. Part 2: Screening, days 1 through 358 and end of study.
Secondary Pharmacokinetic: Cmax To evaluate branaplam pharmacokinetics in plasma after single and repeated doses of branaplam by determination of Cmax. Parts 1 and 2: Day 1 (Pre-dose + 1, 2, 4, 8 & 24 hours post-dose), Days 2, 3, 5, 8, 29. Part 1: Day 43. Part 2: Day 57, 57, 92 (Pre-dose + 4 & 24 hours post-dose), 94, 99, 274 (Pre-dose + 4 & 24 hours post-dose), 276, 281
See also
  Status Clinical Trial Phase
Completed NCT04851873 - Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) Phase 3
Completed NCT03223051 - Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy N/A
Completed NCT04335942 - Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor N/A
Recruiting NCT05794139 - Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy Phase 2
Not yet recruiting NCT06300996 - Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb N/A
Not yet recruiting NCT00961103 - Motor Development and Orthoses in Spinal Muscular Atrophy (SMA) N/A
Completed NCT02003937 - Aerobic Training in Patients With Spinal Muscular Atrophy Type III N/A
Completed NCT00227266 - Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy Phase 2
Completed NCT00374075 - Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy Phase 1
Enrolling by invitation NCT05539456 - Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
Recruiting NCT05779956 - Personalized Medicine for SMA: a Translational Project
Recruiting NCT03300869 - Natural History of Types 2 and 3 SMA in Taiwan
Recruiting NCT03217578 - Neonatal Spinal Muscular Atrophy (SMA) Screening
Completed NCT01703988 - An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Phase 1/Phase 2
Withdrawn NCT02235090 - Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting N/A
Completed NCT02123186 - Newborn Screening for Spinal Muscular Atrophy N/A
Completed NCT00756821 - A Pilot Study of Biomarkers for Spinal Muscular Atrophy N/A
Completed NCT00004771 - Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease Phase 2
Recruiting NCT05366465 - Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
Recruiting NCT06310421 - Spinal Muscular Atrophy Neonatal Screening Program